Realizing the promise of RWE: A need for greater regulatory clarity
Realizing the promise of RWE: A need for greater regulatory clarity | The Pharmaletter
Summary
As the use of Real-World Evidence (RWE) expands, regulatory ambiguity persists. The article points out that current submission standards, designed for RCTs, struggle with diverse RWD formats, necessitating regulatory modernization to balance reduced data processing burden with maintained scientific review.
Details
As RWE becomes increasingly valuable, regulatory ambiguity remains a significant hurdle. A major barrier is that regulatory submission standards were largely developed for protocol-driven Randomized Controlled Trials (RCTs), making them ill-suited for diverse RWD originating from various healthcare environments (including structured and unstructured data). Converting these datasets requires extensive manual effort, which can obscure data provenance, introduce bias, and lead to the loss of clinically relevant information. In response, the FDA explored HL7 FHIR in April 2025 for structured clinical study data from RWD sources. However, challenges were identified, noting that FHIR was not designed to produce analysis-ready regulatory datasets. The authors suggest that the FDA should evaluate FHIR as part of a broader modernization effort, building upon CDISC's existing FHIR-to-SDTM mapping work. Furthermore, the article recommends that the FDA utilize its existing waiver authority to exempt certain RWD submissions from standard format conversion requirements, thereby reducing operational burden while maintaining rigorous scientific review.
Original content copyright by respective publishers